Past President, AANP University of Mary University of Mary Brownsboro, Alabama
Participants should be aware of the following financial/non-financial relationships: . Salim Virani, MD, PhD, FACC, FAHA, FASPC: Disclosure information not submitted.. Cindy Cooke, DNP, FNP-C, FAANP: Disclosure information not submitted.
In this session, we will discuss practical approaches on how to reduce atherosclerotic cardiovascular disease (ASCVD) risk in both primary and secondary prevention based on the recommendations from the 2018 AHA/ACC Multisociety Cholesterol Management guideline. First, we will discuss an approach to treating high-risk primary prevention patients (i.e. those with LDL cholesterol levels of 190 mg/dL or higher or patients with diabetes). We will then discuss the importance of ASCVD risk assessment followed by specific steps clinicians can take to perform 10-year risk assessment. We will also discuss how clinicians can personalize this risk based on an individual patient and how to selectively use imaging to further reclassify this risk appropriately. In the next half of the presentation, we will discuss practical updates on who to treat dyslipidemia in secondary prevention patients. We will discuss how to rationally use statin and non-statin therapies in such patients.
Learning Objectives:
Discuss practical approaches for the treatment of dyslipidemia in 3 primary prevention populations (LDL-C>190 mg/dl, patients with diabetes, and those without elevated LDL-C or diabetes [pure primary prevention population]).
Why and how we calculate ASCVD risk?
How do we personalize ASCVD risk?
How do we reclassify ASCVD risk when there is uncertainty on the part of the clinician or the patient?
Discuss practical approaches to dyslipidemia treatment in patients for secondary ASCVD prevention.